13F Holdings
中文EN

MEDP Medpace Holdings, Inc.

Services-Commercial Physical & Biological Research · Nasdaq · SEC CIK 1668397 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY20.4%
TTM net income YoY19.6%
TTM EPS YoY25.9%
Revenue 3-yr CAGR16.8%
Net income 3-yr CAGR23.8%

Margins

Gross margin—
Operating margin21.4%
Net margin18.2%
FCF margin23.5%
EBITDA margin22.3%

Returns

ROE117.9%
ROA25.5%
ROIC (approx.)—
Asset turnover1.40x

Leverage & solvency

Liabilities / assets74.6%
Debt / equity0.00x
Current ratio0.83x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.40x
Accruals ratio-10.1%
Payout ratio—
Capex / revenue2.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$2.53B$2.11B$1.89B$1.46B$1.14B
SG&A expense$197.56M$180.18M$161.35M$131.40M$108.42M
Operating income$534.93M$446.87M$336.82M$278.70M$198.62M
Pretax income$542.38M$475.92M$335.68M$282.86M$201.85M
Income tax$91.25M$71.54M$52.87M$37.49M$20.00M
Net income$451.12M$404.39M$282.81M$245.37M$181.85M
EBITDA$562.11M$474.68M$360.95M$297.69M$214.62M
EPS (basic)15.6413.069.207.575.06
EPS (diluted)15.2812.638.887.284.81
Weighted avg. shares (diluted)29.53M32.01M31.84M33.67M37.70M
Balance sheet
Cash & equivalents$497.05M$669.44M$245.45M$28.27M$461.30M
Receivables$402.08M$296.44M$298.40M$253.40M$186.43M
Current assets$989.62M$1.03B$593.83M$333.96M$690.91M
PP&E, net$131.06M$123.61M$120.59M$109.85M$93.15M
Goodwill$662.40M$662.40M$662.40M$662.40M$662.40M
Intangibles$33.42M$34.37M$35.81M$38.01M$41.36M
Total assets$1.98B$2.10B$1.66B$1.35B$1.66B
Current liabilities$1.34B$1.10B$925.13M$803.47M$557.22M
Short-term debt——$0$50.00M$0
Total liabilities$1.52B$1.28B$1.10B$966.11M$707.01M
Shareholders' equity$459.07M$825.54M$558.95M$386.39M$952.93M
Shares outstanding28.37M30.63M30.75M31.09M36.01M
Cash flow statement
Operating cash flow$713.22M$608.82M$433.37M$388.05M$263.33M
Capital expenditure$31.36M$36.55M$36.65M$36.88M$28.27M
Free cash flow$681.87M$572.27M$396.73M$351.17M$235.06M
Investing cash flow-$31.14M-$28.31M-$34.63M-$38.74M-$31.36M
Financing cash flow-$860.39M-$154.01M-$182.64M-$775.77M-$44.45M
Depreciation & amortization$27.18M$27.81M$24.13M$18.99M$16.00M
Stock-based compensation$34.79M$25.51M$20.52M$21.41M$14.47M
Share buybacks$917.39M$169.87M$144.02M$847.85M$62.10M

Free plan shows the latest 5 periods; Pro shows all 11 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.